EFFICACY AND SAFETY OF ACT-280778, A DUAL L- AND T-TYPE CALCIUM CHANNEL BLOCKER, IN PATIENTS WITH MILD-TO-MODERATE ESSENTIAL HYPERTENSION: RESULTS FROM A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO- AND ACTIVE-CONTROLLED TRIAL (REDUCE-1)

被引：0
|
作者：
Dingemanse, J. [1 ]
Otasevic, P. [2 ]
Shakeri-Nejad, K. [1 ]
Klainman, E. [3 ]
Putnikovic, B. [4 ]
Kracker, H. [5 ]
Mueller, M. [1 ]
Zimlichman, R. [6 ,7 ]
机构：
[1] Actel Pharmaceut Ltd, Dept Clin Pharmacol, Allschwil, Switzerland
[2] Univ Belgrade, Dedinije Cardiovasc Inst, Belgrade, Serbia
[3] Givatayim & Israeli Acad Coll, Gefen Cardiac Hlth Ctr, Giv'atayim, Israel
[4] Univ Belgrade, Clin Hosp Ctr Zemun, Belgrade, Serbia
[5] Actelion Pharmaceut Ltd, Dept Biostat, Allschwil, Switzerland
[6] Tel Aviv Univ, Wolfson Med Ctr, IL-69978 Tel Aviv, Israel
[7] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S33 / S33
页数：1
相关论文
共 26 条
  • [1] Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension
    Dingemanse, J.
    Otasevic, P.
    Shakeri-Nejad, K.
    Klainman, E.
    Putnikovic, B.
    Kracker, H.
    Mueller, M. S.
    Zimlichman, R.
    JOURNAL OF HUMAN HYPERTENSION, 2015, 29 (04) : 229 - 235
  • [2] Efficacy and safety of the dual L- and T-type calcium channel blocker, ACT-280778: a proof-of-concept study in patients with mild-to-moderate essential hypertension
    J Dingemanse
    P Otasevic
    K Shakeri-Nejad
    E Klainman
    B Putnikovic
    H Kracker
    M S Mueller
    R Zimlichman
    Journal of Human Hypertension, 2015, 29 : 229 - 235
  • [3] The safety and efficacy of efonidipine, an L- and T-Type dual calcium channel blocker, on heart rate and blood pressure in indian patients with mild-to-moderate essential hypertension
    Jariwala, P.
    Kartik, Jadhav
    EUROPEAN HEART JOURNAL, 2022, 43
  • [4] A randomized double-blind, placebo-, and active-controlled study of T-type calcium channel blocker ABT-639 in patients with diabetic peripheral neuropathic pain
    Ziegler, Dan
    Duan, W. Rachel
    An, Guohua
    Thomas, James W.
    Nothaft, Wolfram
    PAIN, 2015, 156 (10) : 2013 - 2020
  • [5] Efficacy and Safety of the T-Type Calcium Channel Modulator CX-8998 in T-CALM, a Randomized, Double-Blind, Placebo-Controlled, Phase 2a Trial in Participants with Essential Tremor
    Ondo, William
    Papapetropoulos, Spyros
    Lee, Margaret S.
    Versavel, Stacey
    Krouse, Andrew
    Newbold, Evan
    Jinnah, Hyder A.
    Pahwa, Rajesh
    Lyons, Kelly E.
    Zesiewicz, Theresa
    Hedera, Peter
    Handforth, Adrian
    Elder, Jenna
    Versavel, Mark
    Elble, Rodger
    ANNALS OF NEUROLOGY, 2020, 88 : S175 - S175
  • [6] Efficacy and safety of a T-type calcium channel blocker in patients with neuropathic pain: A proof-of-concept, randomized, double-blind and controlled trial
    Kerckhove, N.
    Pereira, B.
    Soriot-Thomas, S.
    Alchaar, H.
    Deleens, R.
    Hieng, V. S.
    Serra, E.
    Lanteri-Minet, M.
    Arcagni, P.
    Picard, P.
    Lefebvre-Kuntz, D.
    Maindet, C.
    Mick, G.
    Balp, L.
    Lucas, C.
    Creach, C.
    Letellier, M.
    Martinez, V.
    Navez, M.
    Delbrouck, D.
    Kuhn, E.
    Piquet, E.
    Bozzolo, E.
    Brosse, C.
    Lietar, B.
    Marcaillou, F.
    Hamdani, A.
    Leroux-Bromberg, N.
    Perier, Y.
    Vergne-Salle, P.
    Gov, C.
    Delage, N.
    Gillet, D.
    Romettino, S.
    Richard, D.
    Mallet, C.
    Bernard, L.
    Lambert, C.
    Dubray, C.
    Duale, C.
    Eschalier, A.
    EUROPEAN JOURNAL OF PAIN, 2018, 22 (07) : 1321 - 1330
  • [7] Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial
    Gold, Linda Stein
    Papp, Kim
    Pariser, David
    Green, Lawrence
    Bhatia, Neal
    Sofen, Howard
    Albrecht, Lorne
    Gooderham, Melinda
    Chen, Mindy
    Paris, Maria
    Wang, Yao
    Duffin, Kristina Callis
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 86 (01) : 77 - 85
  • [8] Efficacy and safety of topical WBI-1001 in patients with mild to moderate psoriasis: results from a randomized double-blind placebo-controlled, phase II trial
    Bissonnette, R.
    Bolduc, C.
    Maari, C.
    Nigen, S.
    Webster, J. M.
    Tang, L.
    Lyle, M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2012, 26 (12) : 1516 - 1521
  • [9] HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
    Ahren, Bo
    Johnson, Susan L.
    Stewart, Murray
    Cirkel, Deborah T.
    Yang, Fred
    Perry, Caroline
    Feinglos, Mark N.
    DIABETES CARE, 2014, 37 (08) : 2141 - 2148
  • [10] Efficacy and Safety Results of Guselkumab in Patients with Active Psoriatic Arthritis over 56 Weeks from a Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study
    Deodhar, Atul A.
    Gottlieb, Alice B.
    Boehncke, Wolf-Henning
    Dong, Bin
    Wang, Yuhua
    Zhuang, Yanli
    Barchuk, William
    Xu, Xie L.
    Hsia, Elizabeth
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
123